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ABSTRACT
This article informs the reader of the current
information available on a novel therapeutic
agent and new class of drug for the treatment of
anemia. The data show promising results for
alternative erythropoietin-stimulating agents
and offers a time line of when Phase III data will
be available. The information on this new drug
and new drug class will change how nephrolo-
gists approach treating anemia within their
patients.





An important function of the kidneys is the
production of erythropoietin, a hormone that
stimulates the production of red blood cells. In
disease states such as chronic kidney disease
(CKD), the kidneys are not functioning at
capacity and there can be a disruption in the
production of erythropoietin that can lead to
anemia. Other causes of anemia in CKD are iron
deficiency and inflammation [1, 2]. Anemia
may be present in all stages of CKD and
increases in prevalence as CKD progresses [2, 3].
Current treatment of anemia includes iron
replacement and use of erythropoeitin (EPO)
analogs. The FDA has issued warnings on the
use of EPO analogs due to a greater risk of death
and serious cardiovascular events [4].
Roxadustat, also known as FD-4592, is a
first-in-class small molecule oral hypoxia-in-
ducible factor prolyl hydroxylase inhibitor
(HIF-PHI) currently in Phase III development
[4, 5]. Fibrogen, Inc. has collaborated with
Astellas Pharma Inc. and AstraZeneca in the
development and commercialization of rox-
adustat and estimates completion of the Phase
III trials for U.S approval in 2017 [6]. This article
is based on previously conducted studies and
does not involve any new studies of human or
animal subjects performed by the authors.
Scientific Summary
Pharmacodynamics
Roxadustat offers a novel way of utilizing the
body’s natural compensatory mechanisms in
response to hypoxia [3, 4, 7]. Hypoxia-inducible
factors (HIF) are transcription factors that
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regulate expression of genes that stimulate ery-
thropoiesis. When the body has normal oxygen
levels, HIF-specific prolyl hydroxylase (HIF-PH)
will degrade HIFa. In hypoxic conditions, such as
at increasing altitudes, HIF-PH activity is
decreased to compensate for the reduced oxygen
concentration. Roxadustat is a HIF-PH Inhibitor
(HIF-PHI) that inhibits the degradation of HIFa.
When HIFa accumulates, it dimerizes with HIFb
and translocates to the nucleus to activate the
transcriptional response to hypoxia by promot-
ing erythropoiesis. Phase I and phase II
roduxadustat trials have provided evidence that
erythropoiesis was stimulated by an accumula-
tion of plasma endogenous erythropoietin and
suppression of hepcidin, an indirect regulator of
iron absorption and utilization [4]. When hep-
cidin levels are suppressed, intestinal absorption
of iron increases and the release of iron from
storage sites are utilized.
Pharmacokinetics
Roxadustat is orally bioavailable with an esti-
mated half-life of 12 h [7]. In a placebo-controlled
dose-ranging study (NCT00761657), selected
patients who were being studied for treatment
efficacy of roxadustat in NDD-CKD were also
evaluated for pharmacokinetic and pharmacody-
namics parameters [4]. Evaluations included
measurement of endogenous erythropoietin
(eEPO), iron indices including total iron-binding
capacity (TIBC) and transferrin saturation (TSAT),
as well as hepcidin levels. When roxadustat was
administered in doses of either 1.0 or 2.0 mg/kg
twice weekly (BIW) or three times weekly (TIW),
eEPOstarted to increasewithin4 hof thedoseand
peaked at 10 h post-dose. Endogenous EPO fell
back to baseline at 24–48 h post-dose regardless of
the dose given. Peak EPO increased with dose but
not with frequency. At 6-week follow-up, there
was a decrease in TSAT and an increase in TIBC in
the roxadustat group, signifying increased iron
utilization, as well as a significant decrease in
hepcidin levels.
Therapeutic Trials
Anemia Treatment in Nondialysis-Dependent
CKD A Phase II randomized placebo-con-
trolled dose-ranging and pharmacodynamics
study of roxadustat (NCT00761657) evaluated
the treatment of anemia in patients with CKD
Stages 3-4 (eGFR: 15–59 mL/min/1.73 m2) with
anemia (Hb B 11.0 g/dL) [4]. Patients were
enrolled to receive doses of either 0.7, 1.0, 1.5,
or 2.0 mg/kg and were then randomized in a 3:1
ratio to receive roxadustat or placebo adminis-
tered as either BIW for 4 weeks or TIW for
26 days. Patients were followed for up to
12 weeks post-treatment. Study patients were
not permitted to receive EPO analogous, intra-
venous iron, androgens, or RBC transfusion. If
patients were on oral iron, they were kept at the
original dose; oral iron was also given at the
investigators’ discretion. The study defined Hb
response as an increase in Hb C 1 g/dL at any
time from Day 1 to the 2-week follow-up. Mean
change in Hb was measured at the end of week
6. A total of 117 patients were randomized and
had comparable baseline characteristics with
the exception of some differences between sex
and race between groups. Hb response was
higher in patients who received roxadustat
compared to placebo. In pooled placebo groups,
13% of patients had a Hb response compared to
roxadustat given at 0.7 mg/kg BIW (60%),
0.7 mg/kg TIW (40%), 1.0 mg/kg BIW (80%),
1.0 mg/kg TIW (91%), and 100% response rates
in patients who received doses of 1.5 and
2.0 mg/kg administered as either BIW or TIW.
The rates of Hb response were dependent on the
dose administered. When patients received
1.5–2.0 mg/kg TIW, they achieved a faster
response in Hb compared to BIW groups. A total
of 52 adverse events were reported in pooled
placebo and roxadustat groups. These AEs were
mostly related to the disease state and did not
have any clinical differences between the two
groups. Serious AEs (SAEs) were reported by 5%
of patients who received roxadustat and 4% of
patients who received placebo. SAEs included
vascular access complications, femoral neck
fracture, noncardiac chest pain, and dyspnea.
There were no incidences of cardiovascular
events, seizure, or thromboembolism reported
during the study. There were two recorded epi-
sodes of moderate exacerbation of hyperten-
sion, excessive fluid weight, and one episode of
elevated ALT, AST, and bilirubin that were
deemed unrelated to the study drug. The most
common side effects of roxadustat were
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diarrhea, headache, back pain, and fatigue. This
evidence is limited to the small population size
studied and the short treatment duration.
Anemia Treatment in Dialysis-Dependent
CKD An open label, randomized study evalu-
ated the effect of roxadustat therapy on anemia
in dialysis patients and the exogenous iron
requirements [3]. A total of 60 patients were
enrolled: 24 patients undergoing hemodialysis
(HD) received no exogenous iron supplement,
12 HD patients and 12 peritoneal dialysis
patients received oral iron, and 12 HD patients
given intravenous (IV) iron. The average oral
iron dose was 71 ± 50 mg, while the IV iron
dose was 50 or 62.5 mg weekly. The mean
weekly dose, administered three times a week,
of roxadustat (4–4.3 mg/kg) varied, but did not
significantly differ amongst groups and was
adjusted based on hemoglobin (Hb) response.
The patients included in this study had an
average age of 50 ± 15 years, were 52%men, the
majority (90%) white, with an average time
since first dialysis of 2.2 ± 0.9 months and a
baseline Hb of 8.3 ± 1 g/dL. Mean Hb increases
of C2 g/dL within 7 weeks was achieved in each
group. In addition, the overall mean change
from baseline of Hb was 3.1 ± 0.2 g/dL. The Hb
response was greater in patients receiving iron
supplement than those who did not; however,
the response was similar regardless of the iron
route of administration. Hepcidin levels
decreased in all iron regimen groups, with the
largest drop (80%) observed in patients on HD
not receiving iron. Other parameters, such as
transferring saturation (TSAT) levels and retic-
ulocyte Hb content, did not change in the
groups receiving iron; however, a decrease was
observed in patients not receiving iron. Adverse
events (AEs) were reported in 50% of all
patients, and these AEs were typical of the
patient population undergoing dialysis. Most
common AEs included hypertension (10%) and
decreased TSAT (6.7%); all other AEs had an
incidence of less than 5%. Two patients had
abnormal electrogardiograms at baseline, while,
through the treatment, one patient developed a
first-degree arteriovenous block, and two
patients had a transient elevation in liver
function tests unrelated to roxadustat. Two
deaths were reported and determined to be
unrelated to roxadustat. This study has a num-
ber of limitations, including small sample size,
open label design, short treatment durations
and lack of comparison with standard of care
such as erythropoetin analogue and iron
therapy.
Anemia Treatment in Patients with Dialy-
sis-Dependent CKD who Previously had Hb
Levels Maintained with Epoetin Alfa A phase
II, randomized, open-label, dose-ranging, active
control study (NCT01147666) evaluated the
safety and efficacy of roxadustat in maintaining
Hb levels in patients on maintenance dialysis
therapy, andwho hadmaintained Hb levels with
the IV EPO analog, epoetin alfa [7]. The study
also evaluated the optimum starting dose and
dose adjustment regimens of roxadustat in this
patient population. ESRD adult patients were
included in the study if they weremaintained on
a three times weekly dialysis schedule for a
duration of C4 months with Hb 9.0–13.5 g/dL
for 8 weeks, and stable EPO analogs at dosages
B450 U/kg/weekk for 4 weeks. The study defined
a Hb response rate as patients whose Hb did not
decrease[0.5 g/dL. Part I of the study was con-
ducted in 52 patients over 6 weeks with an
8-week follow-up to evaluate the roxadustat
doses of 1.0, 1.5, 1.8, or 2.0 mg/kg three times a
week compared to continuation of EPO. Part 2
was 19 weeks with a follow-up of 4 weeks which
evaluated 90 patients in 6 cohorts to evaluate
roxadustat with various starting doses compared
to continuation of EPO analog (median dose of
EPO analog = 90 U/kg/week). In part I of the
study, patients who received the lowest dose of
roxadustat 1.0 mg/kg TIW had a comparable Hb
response rate of -0.5 g/dL or greater from base-
line compared to EPO analog. Roxadustat
doses C1.5 mg/kg TIW maintained a Hb
response rate of 79% compared to a 33%
response rate in patients who received EPO ana-
log (p = 0.03). Pooled roxadustat patients had an
overall mean increase in Hb from baseline of
0.3 g/dL compared to a decrease of 1.0 g/dL in
patients who received EPO analog (p = 0.04)
In Part II of the trial, patients who received
any dose of roxadustat achieved a maintenance
Hb C 11 g/dL over the last 4 weeks of the
850 Adv Ther (2017) 34:848–853
19-week treatment compared to EPO analog
(51% and 36%, respectively). Individual rox-
adustat dose cohorts treated for 19 weeks did
not significantly differ from EPO analog treated
patients in change in Hb at any time. Hb was
maintained with a mean roxadustat dose of
1.68 ± 0.65 mg/kd TIW with starting doses
based on weight or weight tiers. C-reactive
protein (CRP), which increases during an
inflammatory state, was correlated with
increased EPO analog dose used, but there were
no differences in dose requirements of rox-
adustat in patients with inflammation. There
was a greater increase in measured blood EPO
levels 12 h post-treatment in patients who
received EPO analog compared to a modest EPO
increase in patients who received roxadustat.
Pooled patients who received roxadustat had
decreases in hepcidin as well as increases in
reticulocyte Hb content. There were no signifi-
cant differences between the two groups in
regards to change in TSAT, serum iron, and total
cholesterol. Safety profiles were comparable
between roxadustat and EPO analog. In the
safety population, 24.1% and 17% of patients
experienced at least 1 SAE with roxadustat and
EPO analog, respectively. Of roxadustat
patients, 63.9% of patients experienced at least
1 AE and 12% experienced a cardiovascular
composite safety endpoint compared to
patients who received EPO analog, 61.1% and
17%, respectively.
Roxadustat was effective at maintaining Hb
levels in patients with ESRD compared to a wide
range of EPO analog doses not receiving IV iron.
Roxadustat was more effective at
doses C1.5 mg/kg TIW compared to lower and
less frequent doses of roxadustat. Roxadustat
and EPO analog had comparable safety profiles.
Adverse Events
Roxadustat was well tolerated in Phase II trials,
and most documented adverse events were
typical for patients with CKD [3, 4]. Common
documented side effects were diarrhea, head-
ache, back pain, fatigue, and increases in blood
pressure and liver enzymes [3, 4, 7]. Cardiovas-
cular events were comparable in patients who
received roxadustat compared to EPO analog;
however, larger trials must be conducted to
confirm these results [7]. Since HIF-inhibitors
effectively increase EPO and Hb, it can be
hypothesized that there may be potential
long-term cardiovascular and/or malignant side
effects that may become apparent with longer
duration trials and post-marketing analysis.
Ongoing Clinical Trials
There are currently 9 phase III clinical trials
studying the safety, efficacy, and long-term
effects of roxadustat in patients with various
degrees of CKD; including dialysis, non-dialy-
sis-dependent, and on newly initiated dialysis
[6] (Table 1). The trials are comparing the use
of roxadustat in comparison to either placebo
or an active control such as darbepoetin alfa
and epoetin alfa. The long-term effects of rox-
adustat are currently being studied in an
open-label 5-year extension study to evaluate
the safety and efficacy of roxadustat for long-
term maintenance use. This study should yield
some insight into the potential cardiovascular
and malignant side effects that may occur.
CONCLUSIONS
Phase II roxadustat trials have demonstrated the
effectiveness of roxadustat in the treatment of
anemia (defined as Hb increase C1 g/dL) and
maintenance of Hb levels (defined as Hb not
falling more than 0.5 g/dL) in patients with
ND-CKD and dialysis-dependent CKD [3, 4, 7].
Roxadustat has been documented to increase
endogenous EPO and suppress hepcidin which
may have positive effects on the utilization and
mobilization of iron [3, 4]. The efficacy of rox-
adustat is dose-dependent. Doses higher than
1.5 mg/kd TIW may possibly be an alternative to
EPO analog; however, since the use of IV ironwas
prohibited during the study, the ESA may not
have been able to raise Hb by its full potential [7].
The safety profile of roxadustat is comparable to
that of EPO analog; however, data from larger
studies will have to confirm these results. Com-
mon adverse events experienced with the rox-
adustat include diarrhea, headache, back pain,
and fatigue [4]. The data presented are limited
because of the small sample sizes and short
durations of the Phase II trials reviewed [2, 3, 7].
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There are multiple small molecule HIF-in-
hibitors currently in clinical development [8].
Drugs in this class share the same mechanism of
action but differ in dosing and frequency. If the
phase III trials reveal positive results in 2017,
the manufacture of roxadustat expects to file an
NDA in 2018 [5, 6]. This will make roxadustat a
first-in-class HIF-inhibitor.
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Table 1 Ongoing phase III Roxadustat clinical trials





Roxadustat in the treatment of anemia in chronic kidney





Evaluation of efﬁcacy and safety of Roxadustat in the
treatment of anemia in stable dialysis subjects
Epoetin Alfa NCT02273726 June 2017
Safety and efﬁcacy study of Roxadustat to treat anemia in
patients with chronic kidney disease, on dialysis
Epoetin Alfa NCT02174731 February 2017
Roxadustat in the treatment of anemia in chronic kidney
disease patients not requiring dialysis (ALPS)
Placebo NCT01887600 January 2018
Safety and efﬁcacy study of Roxadustat to treat anemia in
patients with chronic kidney disease (CKD), not on dialysis
Placebo NCT02174627 March 2017
Roxadustat in the treatment of anemia in end stage renal





Safety and efﬁcacy study for treatment of anemia in ESRD
newly initiated dialysis patients (himalayas)
Epoetin Alfa NCT02052310 June 2017
A study of FG-4592 for the treatment of anemia in chronic
kidney disease patients not receiving dialysis
Placebo NCT01750190 June 2017
Open label extension study for the long-term efﬁcacy and
safety of FG-4592 in dialysis and non-dialysis chronic
kidney disease patients
N/A NCT01630889 October 2018
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